2024
Salvage lung resection after immunotherapy is feasible and safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open 2024, 20: 141-150. PMID: 39296459, PMCID: PMC11405986, DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patients
2020
Navigating by Stars: Using CMS Star Ratings to Choose Hospitals for Complex Cancer Surgery
Papageorge MV, Resio BJ, Monsalve AF, Canavan M, Pathak R, Mase VJ, Dhanasopon AP, Hoag JR, Blasberg JD, Boffa DJ. Navigating by Stars: Using CMS Star Ratings to Choose Hospitals for Complex Cancer Surgery. JNCI Cancer Spectrum 2020, 4: pkaa059-. PMID: 33134834, PMCID: PMC7583163, DOI: 10.1093/jncics/pkaa059.Peer-Reviewed Original ResearchComplex cancer surgeryCMS star ratingsCancer surgerySafe hospitalReassignment of patientsMedicare Provider AnalysisYears of ageHospital mortalitySurgical outcomesSurgical careMedicare beneficiariesMortality ratePatientsSurgeryHospitalHospital qualityReview filesMedicaid ServicesMortalityOnly modest impactOutcomesStar ratingsModest impactYears